Catalent (NYSE:CTLT) Downgraded by StockNews.com to Sell

Catalent (NYSE:CTLT) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

Other analysts have also recently issued research reports about the stock. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Performance

CTLT stock opened at $60.98 on Friday. The firm has a market cap of $11.07 billion, a PE ratio of -26.98, a P/E/G ratio of 2.37 and a beta of 1.16. Catalent has a 12-month low of $36.74 and a 12-month high of $61.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The business has a 50 day moving average of $59.81 and a 200-day moving average of $58.29.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the business earned ($0.10) EPS. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, sell-side analysts expect that Catalent will post 0.84 earnings per share for the current year.

Insider Activity

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

Several hedge funds have recently made changes to their positions in the company. Brooklyn Investment Group bought a new position in Catalent in the 3rd quarter valued at about $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent in the second quarter worth $42,000. Sentry Investment Management LLC bought a new stake in shares of Catalent during the third quarter worth $53,000. Longfellow Investment Management Co. LLC lifted its position in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.